Beyond Injections: How Oral GLP-1s Will Fit into Obesity Care

This edition covers:

• The newest oral GLP-1s on the market
• Clinical differences between oral and injectable GLP-1s
• How a growing range of options is re-shaping health benefit strategies

Last week, the FDA approved Lilly’s new oral GLP-1 medication, Foundayo™ (orforglipron), several months after the approval of Novo Nordisk’s Wegovy® (semaglutide) pill—the first oral GLP‑1 indicated both for weight management and for reducing cardiovascular risk in adults with obesity or overweight, and established heart disease.

Although oral GLP-1s aren’t entirely new—Rybelsus® has been used for diabetes since 2019—these advances raise important questions: